APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-drug Conjugate for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antibody-drug Conjugate for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026186 pages

Choose your research edition.

Industry ResearchAntibody-drug Conjugate for Cancer Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-drug Conjugate for Cancer Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Antibody-drug Conjugate for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-drug Conjugate for Cancer Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody-drug Conjugate for Cancer Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Antibody-drug Conjugate for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antibody-drug Conjugate for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antibody-drug Conjugate for Cancer include Gilead Sciences, Innate Pharma, Rakuten Medical, Seagen, AstraZeneca, GSK, Pfizer, Roche and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Antibody-drug Conjugate for Cancer market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody-drug Conjugate for Cancer and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody-drug Conjugate for Cancer revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Antibody-drug Conjugate for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

Antibody-drug Conjugate for Cancer Segment by Company

Gilead Sciences

Innate Pharma

Rakuten Medical

Seagen

AstraZeneca

GSK

Pfizer

Roche

Takeda

Antibody-drug Conjugate for Cancer Segment by Type

Hematological Malignancies Drugs

Solid Tumor Drugs

Antibody-drug Conjugate for Cancer Segment by Application

Hospital

Pharmacy

Other

Antibody-drug Conjugate for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugate for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugate for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugate for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Antibody-drug Conjugate for Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody-drug Conjugate for Cancer industry.

Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-drug Conjugate for Cancerrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Hematological Malignancies Drugs Table 3. Key Players of Solid Tumor Drugs Table 4. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Table 6. Key Players of Pharmacy Table 7. Key Players of Other Table 8. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Antibody-drug Conjugate for Cancer Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Antibody-drug Conjugate for Cancer Market Share by Region (2021-2026) Table 11. Global Antibody-drug Conjugate for Cancer Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Antibody-drug Conjugate for Cancer Market Share by Region (2027-2032) Table 13. Antibody-drug Conjugate for Cancer Industry Trends Table 14. Antibody-drug Conjugate for Cancer Industry Drivers Table 15. Antibody-drug Conjugate for Cancer Industry Opportunities and Challenges Table 16. Antibody-drug Conjugate for Cancer Industry Restraints Table 17. Global Antibody-drug Conjugate for Cancer Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Company (2021-2026) Table 19. Global Antibody-drug Conjugate for Cancer Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Antibody-drug Conjugate for Cancer Key Company Head Office and Area Served Table 21. Global Antibody-drug Conjugate for Cancer Company, Product Type & Application Table 22. Global Antibody-drug Conjugate for Cancer Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Antibody-drug Conjugate for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Antibody-drug Conjugate for Cancer Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2021-2026) Table 29. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2027-2032) Table 30. Global Antibody-drug Conjugate for Cancer Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2021-2026) Table 34. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2027-2032) Table 35. Gilead Sciences Company Information Table 36. Gilead Sciences Business Overview Table 37. Gilead Sciences Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio Table 39. Gilead Sciences Recent Development Table 40. Innate Pharma Company Information Table 41. Innate Pharma Business Overview Table 42. Innate Pharma Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio Table 44. Innate Pharma Recent Development Table 45. Rakuten Medical Company Information Table 46. Rakuten Medical Business Overview Table 47. Rakuten Medical Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio Table 49. Rakuten Medical Recent Development Table 50. Seagen Company Information Table 51. Seagen Business Overview Table 52. Seagen Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Seagen Antibody-drug Conjugate for Cancer Product Portfolio Table 54. Seagen Recent Development Table 55. AstraZeneca Company Information Table 56. AstraZeneca Business Overview Table 57. AstraZeneca Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio Table 59. AstraZeneca Recent Development Table 60. GSK Company Information Table 61. GSK Business Overview Table 62. GSK Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. GSK Antibody-drug Conjugate for Cancer Product Portfolio Table 64. GSK Recent Development Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Pfizer Antibody-drug Conjugate for Cancer Product Portfolio Table 69. Pfizer Recent Development Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Roche Antibody-drug Conjugate for Cancer Product Portfolio Table 74. Roche Recent Development Table 75. Takeda Company Information Table 76. Takeda Business Overview Table 77. Takeda Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Takeda Antibody-drug Conjugate for Cancer Product Portfolio Table 79. Takeda Recent Development Table 80. North America Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026) & (US$ Million) Table 81. North America Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032) & (US$ Million) Table 82. North America Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026) & (US$ Million) Table 83. North America Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032) & (US$ Million) Table 84. North America Antibody-drug Conjugate for Cancer Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) Table 86. North America Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) Table 87. Europe Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026) & (US$ Million) Table 88. Europe Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032) & (US$ Million) Table 89. Europe Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026) & (US$ Million) Table 90. Europe Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032) & (US$ Million) Table 91. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) Table 93. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) Table 94. China Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026) & (US$ Million) Table 95. China Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032) & (US$ Million) Table 96. China Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026) & (US$ Million) Table 97. China Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032) & (US$ Million) Table 98. Asia Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026) & (US$ Million) Table 99. Asia Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032) & (US$ Million) Table 100. Asia Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026) & (US$ Million) Table 101. Asia Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032) & (US$ Million) Table 102. Asia Antibody-drug Conjugate for Cancer Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) Table 104. Asia Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) Table 105. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026) & (US$ Million) Table 106. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032) & (US$ Million) Table 107. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026) & (US$ Million) Table 108. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032) & (US$ Million) Table 109. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026) Table 111. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Antibody-drug Conjugate for Cancer Product Image Figure 2. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Antibody-drug Conjugate for Cancer Market Share by Type: 2025 VS 2032 Figure 4. Hematological Malignancies Drugs Image Figure 5. Solid Tumor Drugs Image Figure 6. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Antibody-drug Conjugate for Cancer Market Share by Application: 2025 VS 2032 Figure 8. Hospital Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Antibody-drug Conjugate for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 13. Global Antibody-drug Conjugate for Cancer Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Antibody-drug Conjugate for Cancer Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Antibody-drug Conjugate for Cancer Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Antibody-drug Conjugate for Cancer Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2021-2032) Figure 20. Global Antibody-drug Conjugate for Cancer Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2021-2032) Figure 22. North America Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 23. North America Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032) Figure 24. North America Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032) Figure 25. North America Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 26. United States Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 27. Canada Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 29. Europe Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 30. Europe Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032) Figure 31. Europe Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032) Figure 32. Europe Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 33. Germany Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 34. France Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 36. Italy Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 37. Russia Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 39. China Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 40. China Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032) Figure 41. China Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032) Figure 42. Asia Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 43. Asia Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032) Figure 44. Asia Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032) Figure 45. Asia Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 46. Japan Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 50. India Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 51. Australia Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032) Figure 56. Brazil Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 61. UAE Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 63. Chile Antibody-drug Conjugate for Cancer Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Hematological Malignancies Drugs
  • Solid Tumor Drugs
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Gilead Sciences
  • Innate Pharma
  • Rakuten Medical
  • Seagen
  • AstraZeneca
  • GSK
  • Pfizer
  • Roche
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Hematological Malignancies Drugs
  5. 1.2.3 Solid Tumor Drugs
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Antibody-drug Conjugate for Cancer Growth Trends by Region
  13. 1.5.1 Global Antibody-drug Conjugate for Cancer Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Antibody-drug Conjugate for Cancer Market Size by Region (2021-2026)
  15. 1.5.3 Antibody-drug Conjugate for Cancer Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Antibody-drug Conjugate for Cancer Market Dynamics
  1. 2.1 Antibody-drug Conjugate for Cancer Industry Trends
  2. 2.2 Antibody-drug Conjugate for Cancer Industry Drivers
  3. 2.3 Antibody-drug Conjugate for Cancer Industry Opportunities and Challenges
  4. 2.4 Antibody-drug Conjugate for Cancer Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Antibody-drug Conjugate for Cancer Revenue by Company (2021-2026)
  2. 3.2 Global Antibody-drug Conjugate for Cancer Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Antibody-drug Conjugate for Cancer Key Company Head office and Area Served
  4. 3.4 Global Antibody-drug Conjugate for Cancer Company, Product Type & Application
  5. 3.5 Global Antibody-drug Conjugate for Cancer Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Antibody-drug Conjugate for Cancer Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Antibody-drug Conjugate for Cancer Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Antibody-drug Conjugate for Cancer Tier 1, Tier 2, and Tier 3
4 Antibody-drug Conjugate for Cancer Market by Type
  1. 4.1 Global Antibody-drug Conjugate for Cancer Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Antibody-drug Conjugate for Cancer Market Size by Type (2021-2032)
  3. 4.3 Global Antibody-drug Conjugate for Cancer Market Size Share by Type (2021-2032)
5 Antibody-drug Conjugate for Cancer Market by Application
  1. 5.1 Global Antibody-drug Conjugate for Cancer Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Antibody-drug Conjugate for Cancer Market Size by Application (2021-2032)
  3. 5.3 Global Antibody-drug Conjugate for Cancer Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Gilead Sciences
  2. 6.1.1 Gilead Sciences Company Information
  3. 6.1.2 Gilead Sciences Business Overview
  4. 6.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Gilead Sciences Antibody-drug Conjugate for Cancer Product Portfolio
  6. 6.1.5 Gilead Sciences Recent Developments
  7. 6.2 Innate Pharma
  8. 6.2.1 Innate Pharma Company Information
  9. 6.2.2 Innate Pharma Business Overview
  10. 6.2.3 Innate Pharma Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Innate Pharma Antibody-drug Conjugate for Cancer Product Portfolio
  12. 6.2.5 Innate Pharma Recent Developments
  13. 6.3 Rakuten Medical
  14. 6.3.1 Rakuten Medical Company Information
  15. 6.3.2 Rakuten Medical Business Overview
  16. 6.3.3 Rakuten Medical Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Rakuten Medical Antibody-drug Conjugate for Cancer Product Portfolio
  18. 6.3.5 Rakuten Medical Recent Developments
  19. 6.4 Seagen
  20. 6.4.1 Seagen Company Information
  21. 6.4.2 Seagen Business Overview
  22. 6.4.3 Seagen Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Seagen Antibody-drug Conjugate for Cancer Product Portfolio
  24. 6.4.5 Seagen Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 AstraZeneca Antibody-drug Conjugate for Cancer Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 GSK
  32. 6.6.1 GSK Company Information
  33. 6.6.2 GSK Business Overview
  34. 6.6.3 GSK Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 GSK Antibody-drug Conjugate for Cancer Product Portfolio
  36. 6.6.5 GSK Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Pfizer Antibody-drug Conjugate for Cancer Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 Roche
  44. 6.8.1 Roche Company Information
  45. 6.8.2 Roche Business Overview
  46. 6.8.3 Roche Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Roche Antibody-drug Conjugate for Cancer Product Portfolio
  48. 6.8.5 Roche Recent Developments
  49. 6.9 Takeda
  50. 6.9.1 Takeda Company Information
  51. 6.9.2 Takeda Business Overview
  52. 6.9.3 Takeda Antibody-drug Conjugate for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Takeda Antibody-drug Conjugate for Cancer Product Portfolio
  54. 6.9.5 Takeda Recent Developments
7 North America
  1. 7.1 North America Antibody-drug Conjugate for Cancer Market Size (2021-2032)
  2. 7.2 North America Antibody-drug Conjugate for Cancer Market Size by Type
  3. 7.2.1 North America Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026)
  4. 7.2.2 North America Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032)
  5. 7.2.3 North America Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032)
  6. 7.3 North America Antibody-drug Conjugate for Cancer Market Size by Application
  7. 7.3.1 North America Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026)
  8. 7.3.2 North America Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032)
  9. 7.3.3 North America Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032)
  10. 7.4 North America Antibody-drug Conjugate for Cancer Market Size by Country
  11. 7.4.1 North America Antibody-drug Conjugate for Cancer Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
  13. 7.4.3 North America Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
  14. 7.4.4 North America Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Antibody-drug Conjugate for Cancer Market Size (2021-2032)
  2. 8.2 Europe Antibody-drug Conjugate for Cancer Market Size by Type
  3. 8.2.1 Europe Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026)
  4. 8.2.2 Europe Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032)
  5. 8.2.3 Europe Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032)
  6. 8.3 Europe Antibody-drug Conjugate for Cancer Market Size by Application
  7. 8.3.1 Europe Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026)
  8. 8.3.2 Europe Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032)
  9. 8.3.3 Europe Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032)
  10. 8.4 Europe Antibody-drug Conjugate for Cancer Market Size by Country
  11. 8.4.1 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
  13. 8.4.3 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
  14. 8.4.4 Europe Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Antibody-drug Conjugate for Cancer Market Size (2021-2032)
  2. 9.2 China Antibody-drug Conjugate for Cancer Market Size by Type
  3. 9.2.1 China Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026)
  4. 9.2.2 China Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032)
  5. 9.2.3 China Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032)
  6. 9.3 China Antibody-drug Conjugate for Cancer Market Size by Application
  7. 9.3.1 China Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026)
  8. 9.3.2 China Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032)
  9. 9.3.3 China Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Antibody-drug Conjugate for Cancer Market Size (2021-2032)
  2. 10.2 Asia Antibody-drug Conjugate for Cancer Market Size by Type
  3. 10.2.1 Asia Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026)
  4. 10.2.2 Asia Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032)
  5. 10.2.3 Asia Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032)
  6. 10.3 Asia Antibody-drug Conjugate for Cancer Market Size by Application
  7. 10.3.1 Asia Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026)
  8. 10.3.2 Asia Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032)
  9. 10.3.3 Asia Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032)
  10. 10.4 Asia Antibody-drug Conjugate for Cancer Market Size by Country
  11. 10.4.1 Asia Antibody-drug Conjugate for Cancer Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
  13. 10.4.3 Asia Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
  14. 10.4.4 Asia Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Antibody-drug Conjugate for Cancer Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst